BidaskClub Upgrades Omeros (OMER) to Sell

BidaskClub upgraded shares of Omeros (NASDAQ:OMER) from a strong sell rating to a sell rating in a research report released on Friday.

A number of other research analysts also recently issued reports on the stock. ValuEngine upgraded shares of Omeros from a sell rating to a hold rating in a research report on Friday. Maxim Group raised their price target on shares of Omeros from $24.00 to $25.00 and gave the stock a buy rating in a research report on Thursday. HC Wainwright set a $30.00 price target on shares of Omeros and gave the stock a buy rating in a research report on Monday, March 5th. Needham & Company LLC downgraded shares of Omeros from a buy rating to a hold rating and set a $9.01 price target on the stock. in a research report on Friday, March 2nd. Finally, Cantor Fitzgerald set a $19.00 price target on shares of Omeros and gave the stock a hold rating in a research report on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Omeros has an average rating of Hold and an average target price of $25.88.

How to Become a New Pot Stock Millionaire

Omeros (OMER) traded down $1.66 during midday trading on Friday, reaching $14.09. 3,556,771 shares of the company’s stock were exchanged, compared to its average volume of 1,902,012. Omeros has a 12-month low of $8.36 and a 12-month high of $27.09. The company has a quick ratio of 4.10, a current ratio of 4.12 and a debt-to-equity ratio of -29.93. The company has a market cap of $760.50, a P/E ratio of -12.04 and a beta of 3.57.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.03). The business had revenue of $13.76 million for the quarter, compared to analysts’ expectations of $21.94 million. During the same quarter last year, the business earned ($0.45) EPS. Omeros’s revenue was up 6.7% compared to the same quarter last year. research analysts predict that Omeros will post -0.76 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Ingalls & Snyder LLC increased its holdings in shares of Omeros by 3.4% in the 4th quarter. Ingalls & Snyder LLC now owns 5,335,239 shares of the biopharmaceutical company’s stock worth $103,664,000 after acquiring an additional 174,204 shares during the period. Capital Analysts LLC increased its holdings in shares of Omeros by 885.6% in the 4th quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock worth $36,125,000 after acquiring an additional 530,899 shares during the period. Stifel Financial Corp increased its holdings in shares of Omeros by 10.7% in the 3rd quarter. Stifel Financial Corp now owns 394,428 shares of the biopharmaceutical company’s stock worth $8,522,000 after acquiring an additional 38,268 shares during the period. Geode Capital Management LLC increased its holdings in shares of Omeros by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 391,649 shares of the biopharmaceutical company’s stock worth $7,609,000 after acquiring an additional 11,667 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Omeros by 5.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 242,039 shares of the biopharmaceutical company’s stock worth $5,233,000 after acquiring an additional 12,080 shares during the period. Institutional investors own 48.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “BidaskClub Upgrades Omeros (OMER) to Sell” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3296296/bidaskclub-upgrades-omeros-omer-to-sell.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Royal Bank of Canada Cuts Eldorado Gold  Price Target to $1.25
Royal Bank of Canada Cuts Eldorado Gold Price Target to $1.25
Liberum Capital Reaffirms “Buy” Rating for Melrose Industries
Liberum Capital Reaffirms “Buy” Rating for Melrose Industries
Boenning Scattergood Reaffirms Buy Rating for Macerich
Boenning Scattergood Reaffirms Buy Rating for Macerich
Cowen Reaffirms “Hold” Rating for Merck & Co.
Cowen Reaffirms “Hold” Rating for Merck & Co.
Pier 1 Imports  Price Target Lowered to $2.25 at Morgan Stanley
Pier 1 Imports Price Target Lowered to $2.25 at Morgan Stanley
Sotheby’s  Receiving Somewhat Positive Media Coverage, Report Shows
Sotheby’s Receiving Somewhat Positive Media Coverage, Report Shows


© 2006-2018 Ticker Report. Google+.